MediLumine’s Post

We can't wait to see you for SNMMI this weekend in Toronto! See comments 👇 for link to schedule meeting with us. Stop by booth SB2 in small business pavilion to learn about our new : - Reagents (new iodinated vitamin E based Fenestra HDVC) - In Vivo Imaging Systems (2D and/or 3D, bioluminescence + fluorescence + SWIR) - Accessories (Mvein Restrainer for Tail Vein Injections) - Services (Tail Vein Injection Dosing) - Softwares (Imalytics Preclinical Image Analysis) #invivoimaging #preclinicalimaging #lifesciences #molecularimaging

Xerra automates the Cryo-Fluorescence Tomography (CFT) workflow in four easy steps. Seamlessly obtain fluorescence + anatomical images that can be overlaid to better visualize drug PK/PD. EMIT Imaging offers both CFT instrumentation & services to support your preclinical research needs. Discover More: https://bit.ly/4ea3r1c #research #CFT #innovation #drugdiscovery

📢 ERBC offers advanced preclinical biodistribution studies using non-invasive in vivo fluorescence imaging. Our experienced team has experience in following a wide range of test items: ✅Nanoparticles ✅Nanomaterials ✅Proteins ✅Antibodies ✅Liposomes This technique allows to follow labelled-compounds biodistribution in live animals over time, using optimized NIR fluorochromes in both naïve and disease models. By combining bioluminescence with fluorescence imaging, we can assess compound colocalization with pathological processes longitudinally. Enhance your drug development with our state-of-the-art imaging technologies! #3Rs #biodistribution #drugdevelopment #NAM #bioluminescence #fluorescenceimaging

I am really proud of the teams of engineers and molecular biology scientists at Excilone! 🚀 They have developed a cutting-edge technology that allows you to obtain molecular data from a 200 µm area selected on a digital slide!  ✨ Come discover how MiniPunch® transforms tissue analysis at hashtag #MEDICA2024, booth L30-7, hall 5. (Düsseldorf, Germany, 11-14 November 2024). ✨ #pathology, #bioinformatics, #personalizedmedicine, #research, #biomedical, #innovation, #medicalimaging, #ESTP, #toxicology

You dreamed of it, we did it ! 😍 Correlate histology and molecular biology with unprecedented precision! Our new innovative solution, MiniPunch® allows you to establish a direct link between regions of interest identified on a digital slide and corresponding molecular analysis data. Thanks to a precise co-registration algorithm, you can now: - Target with extreme precision the areas of your choice for in-depth molecular analyses (sequencing, PCR...) - Visually validate the results of your molecular analyses Our new technology, MiniPunch®, allows you to switch from histology to in-depth molecular analysis in the blink of an eye. MiniPunch® is accurate, user-friendly, compatible with numerous slide scanners and fits perfectly into your laboratory's workflow. Discover new correlations between histological phenotypes and molecular profiles. Come discover how MiniPunch® transforms tissue analysis at #MEDICA2024, booth L30-7, hall 5. (Düsseldorf, Germany, 11-14 November 2024). #pathology #bioinformatics #personalizedmedicine #research #biomedical #innovation #medicalimaging

Voxcan, part of the ERBC GROUP, specializes in non-invasive high-resolution imaging for non-clinical drug development. We offer advanced preclinical biodistribution studies using in vivo fluorescence imaging. ➡️ Our techniques enable real-time observation of labelled compounds' biodistribution with optimized NIR fluorochromes in both naïve and disease models. Combining bioluminescence with fluorescence imaging, we provide insights into compound colocalization with pathological processes over time. #3Rs #biodistribution #drugdevelopment #NAM #bioluminescence #fluorescenceImaging

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 Article by Anzhelika Vorobyeva et al, using #Mediso nanoScan® PET/MRI and SPECT/CT systems. #molecularimaging #preclinical #imaging #cancerresearch

As Jensen Huang (Nvidia CEO) recently said, if you are #excited about making a difference at scale, the intersection of #engineering and #biomedicine is the place to be! Established in April 2019, UC San Diego HUMANOID: Center of Excellence in Human Organoid Research was strategically placed as one of the 4 four pillars of transdisciplinary research within the UC San Diego Institute for Network Medicine (iNetMed). We celebrate that decision today, because HUMANOID is exactly where it needed to be to #make-a-difference at #scale, through its #LowCost solutions, efforts at #modeling and #benchmarking #invariant phenotypes (that withstand inter- and intra-patient #heterogeneity), with a focus on #rigor and #reproducibility. #organoids; #deeplearning; #precisionmedicine; #drugdiscovery; #biomarker.

A new Raman technique could enable live cell imaging at twice the depth of other Raman scattering techniques. The PM-SRST technique developed at the National University of Singapore can be used to study metabolic activities and functional dynamic processes related to drug delivery and therapeutics within live cells and tissues. Read on below for more detail... #RamanSpectroscopy #Biophotonics #LiveCellImaging #3Dimaging #PM-SRST #OpticalBioimaging https://lnkd.in/g_uMyASg

The concept of using a PBD dimer as a prodrug is also found in LigaChem (formerly LegoChem Biosciences)'s platform, where they add a hydrophilic masking moiety to the imine group of PBD to make it inactive. The activation to its active form relies on beta-glucuronidase for linker cleavage. In contrast, Genentech's mechanism for converting the PBD dimer from inactive to active form is more sophisticated. The core of this ADC structure is the TCO-PAB-DOTA linker attached to the PBD dimer, which renders the PBD inactive (prodrugPBD). The TCO undergoes a click reaction with tetrazine to remove the PAB group, thus activating the PBD. Meanwhile, DOTA chelates Indium-111, serving as a radiolabel to track the drug's distribution. If this mechanism works as intended, administering tetrazine when the drug is localized in the tumor could allow for more precise control over PBD activation within the tumor. Why did Genentech pursue this research? We are familiar with Genentech's LY6E ADC, DLYE5953A, which utilizes MMAE and did not advance beyond Phase 1 clinical trials. While the exact reasons for its discontinuation are unclear, it is plausible that adverse events may have contributed. 1. The occurrence of alopecia and IRR was 2-3 times higher compared to VC-MMAE ADCs. This might be due to LY6E expression in the skin and hair follicles, indicating on-target, off-tumor toxicity. 2. Although not highly severe, IRR might be a target-mediated effect since LY6E is expressed in various immune cell populations. Some patients treated with DLYE5953A experienced a reduction in peripheral blood NK cells. 3. In Phase 1 trials, DLYE5953A was tested in NSCLC and HER2-negative MBC patients, with a higher incidence of peripheral neuropathy reported in MBC patients compared to NSCLC patients. As recent literature suggests, ADC drugs' side effects often depend on the payload mechanism. The research team attributed many side effects of DLYE5953A to the MMAE payload. Therefore, using a different payload might yield a different side effect profile. This might have led to the choice of a well-controlled PBD dimer in subsequent studies. Ref: https://lnkd.in/gqwTfCP2